2. Search Result
Search Result
Results for "

autism spectrum disorder

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

7

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-W001083
    3-Hydroxyphenylacetic acid
    1 Publications Verification

    		 Endogenous Metabolite Ferroptosis Glutathione Peroxidase Aldehyde Dehydrogenase (ALDH) Apoptosis Reactive Oxygen Species (ROS) Keap1-Nrf2 Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders .
    3-Hydroxyphenylacetic acid
  • HY-124733A
    LIT-001

    		Oxytocin Receptor Neurological Disease
    LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism .
    LIT-001
  • HY-136684
    BrBzGCp2
    4 Publications Verification

    S-p-Bromobenzylglutathione cyclopentyl diester

    		 Glyoxalase (GLO) Neurological Disease Cancer
    BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor, with a GC50 of 4.23 μM in HL-60 cells. BrBzGCp2 possesses antitumor and neuroprotective activity .
    BrBzGCp2
  • HY-15522
    WAY-267464
    2 Publications Verification

    		 Oxytocin Receptor Neurological Disease
    WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464
  • HY-B2167R
    Docosahexaenoic acid (Standard)

    DHA (Standard); Cervonic acid (Standard)

    		 Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC50 for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .
    Docosahexaenoic acid (Standard)
  • HY-113085
    3-Hydroxyhippuric acid
    1 Publications Verification

    		 Endogenous Metabolite Neurological Disease
    3-Hydroxyhippuric acid is an acylglycine. 3-Hydroxyhippuric acid inhibits kynureninase (Ki=60 μM). The concentration of 3-Hydroxyhippuric acid in autistic experimental groups is higher than that in control groups. 3-Hydroxyhippuric acid is a biomarker for Clostridium and is positively correlated with the content of Clostridium. 3-Hydroxyhippuric acid is one of the major metabolites of catechin-rich and wine polyphenol-rich diets. 3-Hydroxyhippuric acid can be used in the research of neurodegenerative diseases and autism spectrum disorders .
    3-Hydroxyhippuric acid
  • HY-W002199
    6:2 Fluorotelomer alcohol

    6:2 FTOH; 1H,1H,2H,2H-Perfluoro-1-octanol; 2-(Perfluorohexyl)ethanol

    		 Bacterial Apoptosis ERK TNF Receptor Infection Neurological Disease
    6:2 Fluorotelomer alcohol (6:2 FTOH) is an orally active, blood-brain barrier-permeable modulator of cyclin D1 and ETS1. 6:2 Fluorotelomer alcohol downregulates cyclin D1 expression, upregulates ETS1 via the TNF-α/ERK 1/2 pathway, impairs mitochondrial membrane potential and respiratory function, increases reactive oxygen species levels, disrupts calcium homeostasis and activates endoplasmic reticulum stress markers, and induces cell proliferation inhibition and endothelial-mesenchymal transition. Furthermore, 6:2 Fluorotelomer alcohol induces morphological abnormalities in zebrafish embryos and liver developmental damage, while disrupting the brain immune microenvironment in mice, causing systemic toxicity and delayed pup maturation in CD-1 mice. 6:2 Fluorotelomer alcohol also induces cortical neuron apoptosis, glial cell activation, synaptic abnormalities, colonic barrier damage, intestinal dysbiosis and autism spectrum disorder-like symptoms in mice. 6:2 Fluorotelomer alcohol shows no mutagenic, clastogenic, primary skin/eye irritation or skin sensitizing effects, exhibits no selective reproductive toxicity in CD-1 mice, and is classified as GHS Category 4 for acute oral toxicity. 6:2 Fluorotelomer alcohol can be used in studies of neurodevelopmental disorders and autism spectrum disorders .
    6:2 Fluorotelomer alcohol
  • HY-172318
    IAMA-6

    		NKCC Neurological Disease
    IAMA-6 is a selective NKCC1 inhibitor with neuroprotective effects. IAMA-6 can be used for the study of brain conditions, including drug-resistant epilepsy (e.g. temporal lobe epilepsy (TLE) and Dravet syndrome (DrS)), autism spectrum disorders (ASD) and Down syndrome (DoS) .
    IAMA-6
  • HY-132806
    Alogabat

    RG-7816; RO-7017773

    		 GABA Receptor Neurological Disease
    Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
    Alogabat
  • HY-113058
    3-Hydroxyoctanoic acid

    		Endogenous Metabolite Metabolic Disease
    3-Hydroxyoctanoic acid is a hydroxylated fatty acid that has been found in the LPS of Pseudomonas aeruginosa and in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by Pseudomonas oleophores. It is an agonist of the orphan receptor GPR109B, increasing intracellular calcium in human neutrophils endogenously expressing GPR109B. 3-Hydroxycaprylic acid prevents lipolysis in human adipocytes and is upregulated in human plasma in response to a ketogenic diet. Plasma levels of 3-hydroxyoctanoic acid were also increased 3.41-fold in human male runners exhausted on a treadmill and in a mouse model of autism spectrum disorder (ASD) fed a high-glycemic diet.
    3-Hydroxyoctanoic acid
  • HY-108679
    WAY-267464 hydrochloride
    2 Publications Verification

    		 Oxytocin Receptor Neurological Disease
    WAY-267464 (hydrochloride) is a non-peptide oxytocin receptor (OTR) agonist. WAY-267464 (hydrochloride) can impair social recognition memory in rats through a vasopressin 1A receptor antagonist action. WAY-267464 (hydrochloride) can be used for the research of psychiatric disorders, such disorders include autism spectrum disorder, schizophrenia, and social anxiety disorder .
    WAY-267464 hydrochloride
  • HY-N4309
    Lotusine

    		Amylases Glycosidase Neurological Disease Metabolic Disease Cancer
    Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC50 of 30.60 μg/mL against α-amylase and an IC50 of 36.15 μg/mL against α-glucosidase. Lotusine inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G0/G1 cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .
    Lotusine
  • HY-173615
    KTD-092

    		DYRK Neurological Disease Metabolic Disease
    KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimer's disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases .
    KTD-092
  • HY-P11322
    NHIP peptide

    		Amino Acid Derivatives Neurological Disease
    NHIP peptide is a peptide segment containing 20 amino acids located in the nucleus of the cell. NHIP is highly expressed in neuronal derived cells such as LUHMES cells. NHIP peptide can promote the proliferation of 293T cells. NHIP peptide regulates gene networks related to neural development and autism spectrum disorder (ASD) .
    NHIP peptide
  • HY-124733
    LIT-001 free base

    		Oxytocin Receptor Neurological Disease
    LIT-001 free base is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 free base improves social interaction in a mouse model of autism .
    LIT-001 free base
  • HY-W001083R
    3-Hydroxyphenylacetic acid (Standard)

    		Reference Standards Endogenous Metabolite Ferroptosis Glutathione Peroxidase Aldehyde Dehydrogenase (ALDH) Apoptosis Reactive Oxygen Species (ROS) Keap1-Nrf2 Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3-Hydroxyphenylacetic acid (Standard) is the analytical standard of 3-Hydroxyphenylacetic acid (HY-W001083). This product is intended for research and analytical applications. 3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders.
    3-Hydroxyphenylacetic acid (Standard)
  • HY-W001083S1
    3-Hydroxyphenylacetic acid-d5

    		Isotope-Labeled Compounds Endogenous Metabolite Ferroptosis Glutathione Peroxidase Aldehyde Dehydrogenase (ALDH) Apoptosis Reactive Oxygen Species (ROS) Keap1-Nrf2 Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    2-(3-Hydroxyphenyl-2,4,6-d3)acetic-2,2-d2 acid is the deuterium labeled 3-Hydroxyphenylacetic acid (HY-W001083). 3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders.
    3-Hydroxyphenylacetic acid-d5
  • HY-P1426
    AmmTX3

    		Potassium Channel Neurological Disease
    AmmTX3 is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K + currents with a Ki of 131 nM. AmmTX3 induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 can be used in research related to pain, epilepsy, and autism spectrum disorder .
    AmmTX3
  • HY-P10778
    me4 Peptide

    		Amino Acid Derivatives Neurological Disease
    me4 Peptide is a synthetic peptide designed based on the microexon me4 sequence of neuronal CPEB4 protein. me4 Peptide inhibits CPEB4 aggregation. me4 Peptide can be used in the study of disorders associated with autism spectrum disorders .
    me4 Peptide
  • HY-138830A
    (S,S)-TAK-418

    		Histone Demethylase Neurological Disease
    (S,S)-TAK-418 is a potent inhibitor of lysine-specific demethylase 1 (LSD1), demonstrating significant normalization of aberrant gene expression in neurodevelopmental disorders. (S,S)-TAK-418 also ameliorates ASD-like behaviors in rodent models affected by maternal exposure to valproate or poly I:C. (S,S)-TAK-418 modulates gene expression differently across various models and ages, indicating its potential as a therapeutic agent for conditions like autism spectrum disorder and schizophrenia.
    (S,S)-TAK-418
  • HY-163345
    5-HT7R antagonist 2

    		5-HT Receptor Neurological Disease
    5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment .
    5-HT7R antagonist 2
  • HY-P1426A
    AmmTX3 TFA

    		Potassium Channel Neurological Disease
    AmmTX3 TFA is a peptide toxin identified from the venom of the scorpion Androctonus mauretanicus. AmmTX3 TFA is a highly specific blocker of Kv4 channels, which selectively and almost completely blocks transient A-type K + currents with a Ki of 131 nM. AmmTX3 TFA induces epileptiform behaviors and causes death in mice receiving intracerebroventricular injection. AmmTX3 TFA increases the excitability of dentate gyrus granule cells, reduces GABAergic inhibition, enhances and stabilizes the EPSP-spike component of long-term potentiation, and impairs reference memory. AmmTX3 TFA can be used in research related to pain, epilepsy, and autism spectrum disorder .
    AmmTX3 TFA
  • HY-N4309A
    Lotusine hydroxide

    		Amylases Glycosidase Cardiovascular Disease
    Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC50 of 30.60 μg/mL against α-amylase and an IC50 of 36.15 μg/mL against α-glucosidase. Lotusine hydroxide inhibits the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G0/G1 cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .
    Lotusine hydroxide
  • HY-P0267A
    Melanotan (MT)-II acetate

    		Melanocortin Receptor Neurological Disease Metabolic Disease Endocrinology
    Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .
    Melanotan (MT)-II acetate
  • HY-186116A
    LSD1-IN-49 hydrochloride

    		Histone Demethylase Neurological Disease
    LSD1-IN-49 hydrochloride (Compound (±) 1) is an irreversible LSD1/KDM1A inhibitor with an IC50 of 29 nM against hLSD1. LSD1-IN-49 hydrochloride irreversibly inhibits the enzymatic activity of LSD1 by forming an adduct with flavin adenine dinucleotide (FAD) in the binding pocket of LSD1. LSD1-IN-49 hydrochloride is applicable to research related to schizophrenia, autism spectrum disorder and Huntington's disease .
    LSD1-IN-49 hydrochloride
  • HY-W001083S2
    3-Hydroxyphenylacetic acid-d6

    		Isotope-Labeled Compounds Aldehyde Dehydrogenase (ALDH) Apoptosis Keap1-Nrf2 Ferroptosis Endogenous Metabolite Glutathione Peroxidase Reactive Oxygen Species (ROS) Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3-Hydroxyphenylacetic acid-d6 is the deuterium labeled 3-Hydroxyphenylacetic acid (HY-W001083). 3-Hydroxyphenylacetic acid is an orally active flavonoid metabolite produced by intestinal flora, with blood pressure-lowering activity. 3-Hydroxyphenylacetic acid can also inhibit ferroptosis by upregulating the expression of GPX4, thereby improving spermatogenic dysfunction in aged mice. In addition, abnormal levels of 3-Hydroxyphenylacetic acid are closely related to certain diseases, such as autism spectrum disorders .
    3-Hydroxyphenylacetic acid-d6

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: